Get the Stockscreener App
131.68
2.46%
-3.32
Pre-market:
132.11
0.43
+0.33%
Illumina Inc stock is traded at $131.68, with a volume of 3.00M.
It is down -2.46% in the last 24 hours and down -9.85% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$135.00
Open:
$133.99
24h Volume:
3.00M
Relative Volume:
1.70
Market Cap:
$20.88B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-4.9485
EPS:
-26.61
Net Cash Flow:
$546.00M
1W Performance:
-9.91%
1M Performance:
-9.85%
6M Performance:
+21.33%
1Y Performance:
+34.90%
1-Day Range:
$129.72
$134.28
1-Week Range:
$129.15
$145.63
52-Week Range:
$93.51
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ILMN | 131.68 | 20.88B | 4.39B | -1.58B | 546.00M | -26.61 |
| TMO | 512.84 | 195.55B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 233.10 | 166.92B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 128.57 | 36.94B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 194.38 | 35.03B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 418.61 | 33.80B | 3.84B | 866.24M | 792.60M | 9.80 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Connor Clark & Lunn Investment Management Ltd. Buys 114,466 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Myriad Genetics Announces Incorporation of its Proprietary - GlobeNewswire
Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan
(ILMN) Trading Report - Stock Traders Daily
Illumina's Moat in Sequencing Remains Narrow - Morningstar
Illumina gear up to expand TruSight Oncology portfolio - Yahoo Finance
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio - Yahoo Finance
Gene Panel Market: Rapid Growth with Strong Future CAGR and Top - openPR
Victory Capital Management Inc. Has $16.48 Million Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Biological Multiplex Assays Market to Witness Significant - openPR
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
U.S. STOCKS Merck, Microstrategy, Illumina - XM
Illumina announces expansion of TruSight Oncology portfolio - PR Newswire
LMR Partners LLP Acquires Shares of 21,285 Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
RNA Sequencing Market Expected to Experience Positive Growth - openPR
NGS Based RNA Sequencing Market 2024 Analysis of Key Trends, - openPR
Digital Genome Market May See a Big Move | Illumina, GE Healthcare, Inscripta - openPR
How two systems integration scientists ensure a smooth workflow on MiSeq i100 - Illumina
Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now? - Yahoo Finance
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Mutual of America Capital Management LLC - MarketBeat
CIBC Asset Management Inc Reduces Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
NGS & Microarray Training - Illumina
Impax Asset Management Group plc Increases Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
North America Bioinformatics Market Statistical Forecast - openPR
ING Groep NV Raises Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Plato Investment Management Ltd Raises Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Oppenheimer & Co. Inc. Has $5.33 Million Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
DNA Test Kits Market Future Business Opportunities 2024-2031 | - openPR
Instrument Services - Illumina
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
12,000 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Freemont Management S.A. - MarketBeat
Entropy Technologies LP Invests $1.38 Million in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina's SWOT analysis: ngs leader faces competition, aims for growth - Investing.com
Biochips Market Is Booming Worldwide 2024-2031 | Illumina, - openPR
Illumina's SWOT analysis: ngs leader faces competition, aims for growth By Investing.com - Investing.com UK
Urban Illumina 2024 at MDI Gurgaon Illuminates Insights, Entertainment, and Engagement through Disguised Market Research - Passionate In Marketing
Single-cell RNA analysis finds possible genetic drivers of bone cancer - Illumina
Mengis Capital Management Inc. Purchases New Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Consumer Genomics Industry Next Big Thing | Major Giants- Veritas, Illumina, Xcode Life - openPR
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
OVERSEA CHINESE BANKING Corp Ltd Sells 39,734 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina (NASDAQ:ILMN) Receives Equal Weight Rating from Morgan Stanley - MarketBeat
Baillie Gifford & Co. Lowers Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Bioinformatics Services Market: Size, Share, Trends, - openPR
Los Angeles Capital Management LLC Boosts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (ILMN): Unlocking Growth Potential in Genetic Testing and Robotics - Insider Monkey
Illumina Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
WCM Investment Management LLC Has $424.48 Million Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider - GlobeNewswire Inc.
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):